Ray Therapeutics

Ray Therapeutics is a clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision in patients with severe retinal degeneration. Their lead candidate, RTx-015, targets retinal ganglion cells and is currently in a Phase 1 clinical trial for retinitis pigmentosa and choroideremia. The company's approach uses a bioengineered, highly light-sensitive protein to improve visual function regardless of the underlying genetic mutation.

Buy Funded Startups lists

Funding Round: Grant

Funding Amount: $8M

Date: 24-Apr-2025

Investors: California Institute for Regenerative Medicine (CIRM)

Markets: Biotechnology, Gene Therapy, Ophthalmic

HQ: Berkeley, California, United States

Founded: 2021

Website: https://raytherapeutics.com/

LinkedIn: https://www.linkedin.com/company/ray-therapeutics-inc

Twitter: https://twitter.com/RayTherapeutics

Instagram: